Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.74 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.52 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.52 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074104 | 0.86 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL461272 | 0.82 | PTGDR2 (0.53) | PTGDR2PLA2G2APLA2G1BERCC1ERCC5 | |
| SCHEMBL398075 | 0.78 | PTGDR2 (0.75) | PTGDR2PLA2G2APLA2G1BERCC5FEN1 | |
| SCHEMBL2005075 | 0.75 | PTGDR2 (0.62) | PTGDR2PLA2G2APLA2G1B | |
| SCHEMBL7963412 | 0.74 | PLA2G2A (0.65) | PTGDR2PLA2G2APLA2G1B | |
| SCHEMBL400776 | 0.73 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL5437216 | 0.73 | PLA2G2A (0.82) | PTGDR2PLA2G2APLA2G1B | |
| SCHEMBL1939991 | 0.73 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL2002870 | 0.73 | PLA2G2A (0.82) | PTGDR2PLA2G2APLA2G1B | |
| SCHEMBL13802422 | 0.72 | PTGDR2 (0.76) | PTGDR2PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | PTGDR2 13/4885PLA2G2A 1870/4885PLA2G1B 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.